An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer
- 1Iowa State University
Abstract
Systemic immunosuppression promotes metastatic progression and immunotherapy resistance, yet reliable biomarkers and noninvasive tools for longitudinal monitoring remain limited. Building on our finding that CXCL1+ neutrophil abundance in major organs inversely correlates with breast cancer-induced systemic immunosuppression, we developed an imaging-based immunosuppression gauge using CXCR2-expressing cells that mimic CXCL1+ neutrophil trafficking. Following intravenous administration, the biodistribution of engineered CXCR2-overexpressing mesenchymal stem cells or healthy donor neutrophils was imaged at 24 h, with greater organ accumulation indicating lower systemic immunosuppression. These living, distributed biosensors integrate chemokine signals across multiple organs and convert host immune status into an imageable biodistribution pattern. The gauge distinguished tumor aggressiveness at early disease stages, predicted metastatic risk before overt metastatic outgrowth, identified chemoimmunotherapy responders, and informed treatment selection through longitudinal immune monitoring. Mechanistically, nonaggressive tumors failed to induce substantial systemic immunosuppression and were effectively controlled by surgery alone, whereas aggressive tumors continued to drive immunosuppression after resection. Neoadjuvant chemoimmunotherapy produced superior outcomes to adjuvant treatment by intervening before profound immunosuppression developed and more effectively restoring antitumor immunity. Across cancer models, long-term survivors consistently showed resolution of systemic immunosuppression and restoration of immune activity to healthy-host levels. Thus, imaging systemic immunosuppression provides an early, longitudinal indicator of metastatic risk, therapeutic response, and treatment efficacy.
Related
- Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma
- MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice
- Genomic correlates of metastatic competence and progression in human melanoma
- Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
- 628 Vascular-metabolic checkpoint derives immunotherapy resistance in solid tumor
BibTeX
@misc{zhang2026immunosuppression,
title = {{An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer}},
author = {Y. Zhang and J. Wang},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.22.753629},
url = {https://www.biorxiv.org/content/10.64898/2026.09.22.753629v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer
AU - Y. Zhang
AU - J. Wang
PY - 2026
DA - 2026/09/22
PB - bioRxiv
DO - 10.64898/2026.09.22.753629
UR - https://www.biorxiv.org/content/10.64898/2026.09.22.753629v1
AB - Systemic immunosuppression promotes metastatic progression and immunotherapy resistance, yet reliable biomarkers and noninvasive tools for longitudinal monitoring remain limited. Building on our finding that CXCL1+ neutrophil abundance in major organs inversely correlates with breast cancer-induced systemic immunosuppression, we developed an imaging-based immunosuppression gauge using CXCR2-expressing cells that mimic CXCL1+ neutrophil trafficking. Following intravenous administration, the biodistribution of engineered CXCR2-overexpressing mesenchymal stem cells or healthy donor neutrophils was imaged at 24 h, with greater organ accumulation indicating lower systemic immunosuppression. These living, distributed biosensors integrate chemokine signals across multiple organs and convert host immune status into an imageable biodistribution pattern. The gauge distinguished tumor aggressiveness at early disease stages, predicted metastatic risk before overt metastatic outgrowth, identified chemoimmunotherapy responders, and informed treatment selection through longitudinal immune monitoring. Mechanistically, nonaggressive tumors failed to induce substantial systemic immunosuppression and were effectively controlled by surgery alone, whereas aggressive tumors continued to drive immunosuppression after resection. Neoadjuvant chemoimmunotherapy produced superior outcomes to adjuvant treatment by intervening before profound immunosuppression developed and more effectively restoring antitumor immunity. Across cancer models, long-term survivors consistently showed resolution of systemic immunosuppression and restoration of immune activity to healthy-host levels. Thus, imaging systemic immunosuppression provides an early, longitudinal indicator of metastatic risk, therapeutic response, and treatment efficacy.
ER -